RBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
RBC Capital has maintained its Outperform rating for Lexeo Therapeutics (NASDAQ:LXEO) and increased its price target from $22.00 to $24.00. Lexeo's shares have risen 7.11% in the last 24 hours to $15.52. The new price target suggests a potential 54.64% increase from the current price. Lexeo Therapeutics is a clinical-stage genetic medicines company focusing on gene therapies for diseases with high unmet need.
March 12, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital maintains Outperform rating for Lexeo Therapeutics, raising its price target from $22 to $24. Shares have increased by 7.11% to $15.52, indicating positive market response.
The maintenance of an Outperform rating and the increase in price target by RBC Capital are strong positive signals for Lexeo Therapeutics. The stock's recent 7.11% increase reflects a positive market response to this news. Given the company's focus on gene therapies for diseases with high unmet need, the raised price target suggests confidence in Lexeo's pipeline and potential for significant growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100